Reneo Pharmaceuticals Inc. (RPHM)

Stock Card

$1.81

$-15.49 (-89.54%)

As on 04-Oct-2024 18:32EDT

Market cap

$61 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

Reneo Pharmaceuticals (RPHM) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.2
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

3,342,880

5 Years Aggregate

CFO

$-180.07 Mln

EBITDA

$-211.03 Mln

Net Profit

$-199.12 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Reneo Pharmaceuticals (RPHM)	-88.7	-87.3	-88.0	-97.4	-70.7	--	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Oct-2024 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022
Reneo Pharmaceuticals (RPHM)	-31.3	-72.7
S&P Small-Cap 600	13.9	-17.4
BSE Sensex	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Reneo Pharmaceuticals (RPHM)	1.8	60.8	1.5	-56.5	-4,286.6	-68.3	--	0.8
Comera Life Sciences Holdings Inc (CMRA)	0.0	0.7	1.0	-84.3	-917.2	--	--	0.0

Shareholding Pattern

View Details

About Reneo Pharmaceuticals (RPHM)

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and... selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. Read more

Founder & Executive Chairman

Mr. Michael G. Grey
Founder & Executive Chairman

Mr. Michael G. Grey
Headquarters

Irvine, CA
Website

https://reneopharma.com

FAQs for Reneo Pharmaceuticals (RPHM)

What is the current share price of Reneo Pharmaceuticals Inc (RPHM) Today?

The share price of Reneo Pharmaceuticals Inc (RPHM) is $1.81 (NASDAQ) as of 04-Oct-2024 18:32 EDT. Reneo Pharmaceuticals Inc (RPHM) has given a return of -70.72% in the last 3 years.

What is the current PB & PE ratio of Reneo Pharmaceuticals Inc (RPHM)?

Since, TTM earnings of Reneo Pharmaceuticals Inc (RPHM) is negative, P/E ratio is not available.
The P/B ratio of Reneo Pharmaceuticals Inc (RPHM) is 0.79 times as on 04-Oct-2024, a 85 discount to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	--	--
2022	--	--
2021	--	--
2020	--	--
2019	--	--

What is the 52 Week High and Low of Reneo Pharmaceuticals Inc (RPHM)?

The 52-week high and low of Reneo Pharmaceuticals Inc (RPHM) are Rs -- and Rs -- as of 28-Aug-2026.

What is the market cap of Reneo Pharmaceuticals Inc (RPHM)?

Reneo Pharmaceuticals Inc (RPHM) has a market capitalisation of $ 61 Mln as on 04-Oct-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Reneo Pharmaceuticals Inc (RPHM)?

Before investing in Reneo Pharmaceuticals Inc (RPHM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.